EMEA-003121-PIP01-21 - paediatric investigation plan

Human normal immunoglobulin
PIPHuman

Key facts

Invented name
Flebogamma DIF (previously Flebogammadif)
Active Substance
Human normal immunoglobulin
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0094/2022
PIP number
EMEA-003121-PIP01-21
Pharmaceutical form(s)
All pharmaceutical forms
Condition(s) / indication(s)
Treatment of post-polio syndrome
Route(s) of administration
All routes of administration
Contact for public enquiries

Instituto Grifols, S.A.
E-mail: areatecnica.instituto@grifols.com
Tel. +34 935710700

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page